Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study
详细信息 查看全文
- 作者：Sung Hee Lim ; Jong-Mu Sun ; Yoon-La Choi ; Hye Ryun Kim ; Soomin Ahn ; Ji Yun Lee ; Se-Hoon Lee ; Jin Seok Ahn ; Keunchil Park ; Joo Hang Kim ; Byoung Chul Cho and Myung-Ju Ahn
- 刊名：Cancer
- 出版年：2016
- 出版时间：October 1, 2016
- 年：2016
- 卷：122
- 期：19
- 页码：3024-3031
- 全文大小：358K
- ISSN：1097-0142
文摘
Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential driving oncogene in squamous cell cancer (SCC) of the lung. The current phase 2 study evaluated the efficacy and tolerability of dovitinib, an FGFR inhibitor, in patients with advanced SCC of the lung.